A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 26 Jun 2018
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EU-TREAT
- Sponsors Novo Nordisk
- 26 Jun 2018 Results evaluating the effectiveness of degludec after switching from insulin glargine 100 units/mL (glargine U100), under routine care, presented at the 78th Annual Scientific Sessions of the American Diabetes Association.
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
- 06 Nov 2017 According to a Novo Nordisk media release, new analysis of real-world data was presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress.